دورية أكاديمية
أعرض في EDS

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.

التفاصيل البيبلوغرافية
العنوان: Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.
المؤلفون: Howard AJ; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Concepcion I; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Wang AX; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Hamadeh IS; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Hultcrantz M; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Mailankody S; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY., Tan C; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Korde N; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Lesokhin AM; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Hassoun H; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Shah UA; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Maclachlan KH; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Rajeeve S; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY., Landau HJ; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Scordo M; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Shah GL; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Lahoud OB; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Chung DJ; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Giralt S; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Usmani SZ; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Firestone RS; Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
المصدر: Blood advances [Blood Adv] 2024 Jun 25; Vol. 8 (12), pp. 3246-3253.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Society of Hematology, [2016]-
مواضيع طبية MeSH: Multiple Myeloma*/therapy , Immunotherapy, Adoptive*/methods, Humans ; Male ; Middle Aged ; Female ; Retrospective Studies ; Aged ; Antibodies, Bispecific/therapeutic use ; Adult ; Receptors, Chimeric Antigen/therapeutic use ; Quality of Life
مستخلص: Abstract: Outcomes for patients with relapsed/refractory multiple myeloma (R/RMM) have dramatically improved after the development and now growing utilization of B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy. However, health care utilization as a quality-of-life metric in these growing populations has not been thoroughly evaluated. We performed a retrospective cohort study evaluating the frequency and cause of unscheduled health care interactions (UHIs) among patients with R/RMM responding to B-cell maturation antigen-targeted BsAb and CAR T-cell therapies (N = 46). This included the analysis of remote UHIs including calls to physicians' offices and messages sent through an online patient portal. Our results showed that nearly all patients with R/RMM (89%) receiving these therapies required a UHI during the first 125 days of treatment, with a mean of 3.7 UHIs per patient. Patients with R/RMM responding to BsAbs were significantly more likely to remotely contact their physicians' offices (1.8-fold increase; P = .038) or visit an urgent care center (more than threefold increase; P = .012) than patients with R/RMM responding to CAR T-cell therapies. This was largely due to increased reports of mild upper respiratory tract infections in BsAb patients. Our results underscore the need to develop preemptive management strategies for commonly reported symptoms that patients with R/RMM experience while receiving CAR T-cell or BsAb therapies. This preemptive management may significantly reduce unnecessary health care utilization in this vulnerable patient population.
(© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
References: N Engl J Med. 2021 Feb 25;384(8):705-716. (PMID: 33626253)
Blood Cancer Discov. 2023 Nov 1;4(6):433-436. (PMID: 37824758)
BMC Bioinformatics. 2006 Mar 09;7:123. (PMID: 16526949)
Oncol Ther. 2023 Jun;11(2):263-275. (PMID: 37014590)
N Engl J Med. 2022 Sep 29;387(13):1196-1206. (PMID: 36170501)
N Engl J Med. 2023 Mar 16;388(11):1002-1014. (PMID: 36762851)
Lancet Oncol. 2016 Aug;17(8):e328-e346. (PMID: 27511158)
N Engl J Med. 2023 Jul 27;389(4):335-347. (PMID: 37272512)
Blood Adv. 2024 Apr 9;8(7):1600-1611. (PMID: 37878808)
Lancet. 2021 Jul 24;398(10297):314-324. (PMID: 34175021)
Leukemia. 2024 Feb;38(2):365-371. (PMID: 38245601)
Transplant Cell Ther. 2024 Mar;30(3):308.e1-308.e13. (PMID: 38151105)
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):340-347. (PMID: 38066841)
Blood Cancer J. 2023 Aug 1;13(1):116. (PMID: 37528088)
J Clin Oncol. 2023 Apr 10;41(11):2087-2097. (PMID: 36623248)
N Engl J Med. 2022 Aug 11;387(6):495-505. (PMID: 35661166)
Cancer. 2023 Jul 1;129(13):2035-2046. (PMID: 36991547)
Blood Cancer Discov. 2023 Nov 1;4(6):440-451. (PMID: 37769148)
EJHaem. 2023 Sep 23;4(4):1013-1018. (PMID: 38024607)
Blood Cancer J. 2021 Jun 18;11(6):116. (PMID: 34145225)
Blood Adv. 2023 Jul 11;7(13):3069-3074. (PMID: 36857755)
Lancet. 2021 Aug 21;398(10301):665-674. (PMID: 34388396)
J Manag Care Spec Pharm. 2023 Aug;29(8):917-926. (PMID: 37523320)
N Engl J Med. 2022 Dec 15;387(24):2232-2244. (PMID: 36507686)
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. (PMID: 30592986)
Curr Oncol. 2023 Jul 01;30(7):6330-6352. (PMID: 37504327)
Br J Haematol. 2024 Apr;204(4):1293-1299. (PMID: 38263627)
Blood Adv. 2023 Oct 10;7(19):5898-5903. (PMID: 37467036)
المشرفين على المادة: 0 (Antibodies, Bispecific)
0 (Receptors, Chimeric Antigen)
تواريخ الأحداث: Date Created: 20240415 Date Completed: 20240614 Latest Revision: 20240708
رمز التحديث: 20240708
مُعرف محوري في PubMed: PMC11226971
DOI: 10.1182/bloodadvances.2024012871
PMID: 38621239
قاعدة البيانات: MEDLINE
الوصف
تدمد:2473-9537
DOI:10.1182/bloodadvances.2024012871